OG2 Inhibitoren

Common OG2 Inhibitors include, but are not limited to Retinoic Acid, all trans CAS 302-79-4, 5,5-Diphenyl Hydantoin CAS 57-41-0, SB 431542 CAS 301836-41-9, Alendronate acid CAS 66376-36-1 and 6-Propyl-2-thiouracil CAS 51-52-5.

Osteocalcin, also known as bone gamma-carboxyglutamic acid-containing protein (BGLAP), is a non-collagenous protein found primarily in the extracellular matrix of bone. Produced by osteoblasts, osteocalcin is involved in the regulation of bone mineralization, acting as a facilitator in the deposition of calcium ions onto the bone matrix. Its synthesis and secretion are tightly regulated by various hormones and vitamins, most notably vitamin D and parathyroid hormone. Osteocalcin is unique in that it undergoes post-translational carboxylation of specific glutamate residues, which allows it to bind strongly to hydroxyapatite, the primary mineral component of bone. This binding plays a pivotal role in anchoring the protein within the bone matrix and ensuring the proper mineralization of bone tissue. Beyond its role in bone metabolism, osteocalcin has also been identified in other tissues and has been implicated in several other physiological processes, including energy metabolism and glucose regulation.

Osteocalcin inhibitors are compounds that specifically target and reduce the activity or levels of osteocalcin. These inhibitors can act through various mechanisms. Some may inhibit the synthesis or secretion of osteocalcin by osteoblasts, while others might block its post-translational modifications, thereby affecting its ability to bind to hydroxyapatite. Still, others could impede its interaction with other proteins or cellular components crucial for its function. Given osteocalcin's role in bone mineralization, these inhibitors can modulate bone density and structure.